Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF-κB Activation in Osteosarcoma U2OS Cells
- PMID: 28870912
- DOI: 10.21873/anticanres.11900
Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF-κB Activation in Osteosarcoma U2OS Cells
Abstract
The study goal was to investigate effect of amentoflavone on nuclear factor-κB (NF-κB)-modulated metastatic mechanism in osteosarcoma U2OS cells. U2OS cells were treated with amentoflavone, NF-κB inhibitor, protein kinase B (PKB or AKT) inhibitor or mitogen-activated protein kinase (MAPK) inhibitor. Change of cell viability, NF-κB activation, expression of metastasis-associated proteins, signal transduction, and cell migration and invasion were evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, NF-κB reporter gene assay, western blotting, and cell migration and invasion assays. The results demonstrated that inhibition of activation of extracellular signal-regulated kinases (ERK) was a key point for suppression of NF-κB-modulated metastatic mechanism. Amentoflavone significantly inhibited NF-κB activation, ERK phosphorylation, expression of metastasis-associated proteins, and cell migration and invasion. Our findings indicate that amentoflavone reduces metastatic potential through suppression of ERK and NF-κB activation in osteosarcoma U2OS cells.
Keywords: Amentoflavone; NF-κB; metastasis; nuclear factor-κB; osteosarcoma.
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid.Front Pharmacol. 2021 Dec 22;12:768708. doi: 10.3389/fphar.2021.768708. eCollection 2021. Front Pharmacol. 2021. PMID: 35002708 Free PMC article. Review.
-
Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma In Vitro.In Vivo. 2018 May-Jun;32(3):549-554. doi: 10.21873/invivo.11274. In Vivo. 2018. PMID: 29695559 Free PMC article.
-
Suppression of ERK/NF-κB Activation Is Associated With Amentoflavone-Inhibited Osteosarcoma Progression In Vivo.Anticancer Res. 2019 Jul;39(7):3669-3675. doi: 10.21873/anticanres.13515. Anticancer Res. 2019. PMID: 31262893
-
Amentoflavone Induces Anti-angiogenic and Anti-metastatic Effects Through Suppression of NF-κB Activation in MCF-7 cells.Anticancer Res. 2015 Dec;35(12):6685-93. Anticancer Res. 2015. PMID: 26637885
-
Information Theory: New Look at Oncogenic Signaling Pathways.Trends Cell Biol. 2019 Nov;29(11):862-875. doi: 10.1016/j.tcb.2019.08.005. Epub 2019 Oct 17. Trends Cell Biol. 2019. PMID: 31630880 Review.
Cited by
-
Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid.Front Pharmacol. 2021 Dec 22;12:768708. doi: 10.3389/fphar.2021.768708. eCollection 2021. Front Pharmacol. 2021. PMID: 35002708 Free PMC article. Review.
-
Lycorine inhibits tumor growth of human osteosarcoma cells by blocking Wnt/β-catenin, ERK1/2/MAPK and PI3K/AKT signaling pathway.Am J Transl Res. 2020 Sep 15;12(9):5381-5398. eCollection 2020. Am J Transl Res. 2020. PMID: 33042426 Free PMC article.
-
Inactivation of EGFR/ERK/NF-κB signalling associates with radiosensitizing effect of 18β-glycyrrhetinic acid on progression of hepatocellular carcinoma.J Cell Mol Med. 2023 Jun;27(11):1539-1549. doi: 10.1111/jcmm.17760. Epub 2023 May 12. J Cell Mol Med. 2023. PMID: 37177859 Free PMC article.
-
Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppression of NF‑κB signaling.Mol Med Rep. 2020 Sep;22(3):2386-2394. doi: 10.3892/mmr.2020.11304. Epub 2020 Jul 6. Mol Med Rep. 2020. PMID: 32705250 Free PMC article.
-
The roles of glycolysis in osteosarcoma.Front Pharmacol. 2022 Aug 17;13:950886. doi: 10.3389/fphar.2022.950886. eCollection 2022. Front Pharmacol. 2022. PMID: 36059961 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous